Filing Details
- Accession Number:
- 0001567619-22-010101
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-11 17:59:33
- Reporting Period:
- 2022-05-09
- Accepted Time:
- 2022-05-11 17:59:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1630627 | Treace Medical Concepts Inc. | TMCI | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1185249 | R John Treace | C/O Treace Medical Concepts, Inc. 203 Fort Wade Road, Suite 150 Ponte Vedra FL 32081 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-05-09 | 37,312 | $13.30 | 1,860,478 | No | 4 | S | Indirect | John R. Treace and Ginger D. Treace JTTEN |
Common Stock | Disposition | 2022-05-09 | 18,966 | $14.20 | 1,841,512 | No | 4 | S | Indirect | John R. Treace and Ginger D. Treace JTTEN |
Common Stock | Disposition | 2022-05-09 | 18,415 | $15.22 | 1,823,097 | No | 4 | S | Indirect | John R. Treace and Ginger D. Treace JTTEN |
Common Stock | Disposition | 2022-05-09 | 307 | $15.97 | 1,822,790 | No | 4 | S | Indirect | John R. Treace and Ginger D. Treace JTTEN |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | John R. Treace and Ginger D. Treace JTTEN |
No | 4 | S | Indirect | John R. Treace and Ginger D. Treace JTTEN |
No | 4 | S | Indirect | John R. Treace and Ginger D. Treace JTTEN |
No | 4 | S | Indirect | John R. Treace and Ginger D. Treace JTTEN |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 408,816 | Indirect | As Co-Trustee of the John R. Treace Irrevocable Trust dated July 29, 2021 |
Footnotes
- Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.93 to $13.86 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $13.93 to $14.86 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.93 to $15.891 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.96 to $15.97 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The Reporting Person disclaims beneficial ownership of shares held in trusts for which his spouse is a co-trustee.